{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:09Z","timestamp":1761871089513,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.clml.2017.09.001","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T18:01:09Z","timestamp":1505844069000},"page":"58-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed\/Refractory Mantle-Cell and Indolent Lymphomas"],"prefix":"10.1016","volume":"18","author":[{"given":"Soham D.","family":"Puvvada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Guillen-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijeet","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lora","family":"Incl\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara","family":"Heard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier I.","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-7439","authenticated-orcid":false,"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1842-228X","authenticated-orcid":false,"given":"Jonathan H.","family":"Schatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daruka","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel O.","family":"Persky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.09.001_bib1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.09.001_bib2","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/annonc\/mdt070","article-title":"A\u00a0phase II multicenter trial of hyperCVAD MTX\/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma. SWOG 0213","volume":"24","author":"Bernstein","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.09.001_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.001_bib4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1634\/theoncologist.7-3-217","article-title":"Progress and promise in the treatment of indolent lymphomas","volume":"7","author":"McLaughlin","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2017.09.001_bib5","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.001_bib6","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.09.001_bib7","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(11)70150-4","article-title":"Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial","volume":"12","author":"Coiffier","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2017.09.001_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1756-8722-5-67","article-title":"Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naive or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial","volume":"5","author":"Zinzani","year":"2012","journal-title":"J\u00a0Hematol Oncol"},{"issue":"suppl","key":"10.1016\/j.clml.2017.09.001_bib9","article-title":"Effect of bortezomib on complete remission (CR) rate when added to bendamustine\u2013rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): a randomized phase II trial of the ECOG-ACRIN Cancer Research Group","volume":"34","author":"Evens","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.001_bib10","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1073\/pnas.81.7.2232","article-title":"Antileukemic and immunosuppressive activity of 2-chloro-2\u2032-deoxyadenosine","volume":"81","author":"Carson","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2017.09.001_bib11","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1517\/13543780903071038","article-title":"Cladribine: not just another purine analogue?","volume":"18","author":"Spurgeon","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clml.2017.09.001_bib12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood-2010-04-278507","article-title":"Proteasome and HDAC: who\u2019s zooming who?","volume":"116","author":"McConkey","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.001_bib13","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/j.1349-7006.2009.01162.x","article-title":"Phase I\/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab","volume":"100","author":"Tobinai","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2017.09.001_bib14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1532\/IJH97.04077","article-title":"Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin\u2019s lymphomas: results of a Japanese phase II study","volume":"80","author":"Ogura","year":"2004","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2017.09.001_bib15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1008325110921","article-title":"Fludarabine and cladribine in relapsed\/refractory low-grade non-Hodgkin\u2019s lymphoma: a phase II randomized study","volume":"11","author":"Tondini","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.09.001_bib16","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/(SICI)1097-0142(19981201)83:11<2370::AID-CNCR17>3.0.CO;2-M","article-title":"Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin\u2019s lymphoma","volume":"83","author":"Tulpule","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.09.001_bib17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/10428199709114170","article-title":"Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin\u2019s lymphoma","volume":"25","author":"Liliemark","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.09.001_bib18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.23537","article-title":"Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group","volume":"113","author":"Inwards","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.09.001_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/EDBK_159514","article-title":"Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute\u2019s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"35","author":"Kluetz","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clml.2017.09.001_bib20","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.001_bib21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.001_bib23","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2017.09.001_bib24","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.001_bib25","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo\u2013purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.001_bib26","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3109\/10428194.2011.575489","article-title":"Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma","volume":"52","author":"Spurgeon","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.09.001_bib27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1600-0609.2010.01552.x","article-title":"Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma","volume":"86","author":"Nagai","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2017.09.001_bib28","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1182\/blood.V124.21.1714.1714","article-title":"Final results of a phase 1-2 study of vorinostat (SAHA), cladribine, and rituximab (SCR) relapsed B-cell non-Hodgkin\u2019s lymphoma and previously untreated mantle cell lymphoma","volume":"124","author":"Spurgeon","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.001_bib29","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/annonc\/mdu273","article-title":"Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma","volume":"25","author":"Inwards","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.09.001_bib30","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3324\/haematol.2012.072587","article-title":"Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie","volume":"98","author":"Troch","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.09.001_bib31","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.001_bib32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.09.001_bib33","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.001_bib34","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.09.001_bib35","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.09.001_bib36","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2014-11-567792","article-title":"Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities","volume":"125","author":"Kritharis","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.09.001_bib37","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2017.09.001_bib38","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2016.68.2856","article-title":"Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States","volume":"35","author":"Chen","year":"2016","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017305918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017305918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:20Z","timestamp":1761870620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017305918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S2152265017305918"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.09.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed\/Refractory Mantle-Cell and Indolent Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}